[Testosterone Replacement Therapy and Prostate Cancer. The Current Position 67 Years After the Huggins Myth]

Overview

Journal Urologe A

Specialty Urology

Date 2009 Mar 20

PMID 19296069

Citations 1

Authors

L Rinnab

K Gust

R E Hautmann

R Kufer

Affiliations

Soon will be listed here.

Abstract

Hypogonadism is highly prevalent in the elderly and in men with prostate cancer. Symptoms of hypogonadism, such as depression, lack of libido, and decreased bone mineral density, can significantly impair quality of life. In addition, testosterone plays an important role in erectile preservation and in growth and function of the cavernosal and penile nerves. There are compelling data showing that testosterone replacement therapy (TRT) does not increase the risk of prostate cancer. The literature (four published studies) concerning men treated with TRT after definitive therapy for prostate cancer reports only one biochemical recurrence. Based on these data, physicians cannot really justify withholding TRT from symptomatic patients after they have been successful treated for prostate cancer. This review gives the practising urologist an overview of the latest literature and useful advice on this controversial topic.

Citing Articles

Antidepressant-Like Effect of Ropren® in β-Amyloid-(25-35) Rat Model of Alzheimer's Disease with Altered Levels of Androgens.

Soultanov V, Fedotova J, Nikitina T, Roschin V, Ordyan N, Hritcu L Mol Neurobiol. 2016; 54(4):2611-2621.

PMID: 26993300 DOI: 10.1007/s12035-016-9848-8.

References

Bhasin S, Singh A, Mac R, Carter B, Lee M, Cunningham G . Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003; 24(3):299-311. DOI: 10.1002/j.1939-4640.2003.tb02676.x. View

Morgentaler A, Bruning 3rd C, DeWolf W . Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996; 276(23):1904-6. View

Syme D, Corcoran N, Bouchier-Hayes D, Morrison W, Costello A . The effect of androgen status on the structural and functional success of cavernous nerve grafting in an experimental rat model. J Urol. 2006; 177(1):390-4. DOI: 10.1016/j.juro.2006.08.077. View

. Report of National Institute on Aging Advisory Panel on Testosterone Replacement in Men. J Clin Endocrinol Metab. 2001; 86(10):4611-4. DOI: 10.1210/jcem.86.10.7942. View

Morgentaler A . Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006; 50(5):935-9. DOI: 10.1016/j.eururo.2006.06.034. View

Sarosdy M . Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2006; 109(3):536-41. DOI: 10.1002/cncr.22438. View

Wang C, Swerdloff R, Iranmanesh A, Dobs A, Snyder P, Cunningham G . Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000; 85(8):2839-53. DOI: 10.1210/jcem.85.8.6747. View

Fowler Jr J, WHITMORE Jr W . The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol. 1981; 126(3):372-5. DOI: 10.1016/s0022-5347(17)54531-0. View

Guay A, Perez J, Jacobson J, NEWTON R . Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl. 2001; 22(5):793-7. View

10.

Kaufman J, Graydon R . Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004; 172(3):920-2. DOI: 10.1097/01.ju.0000136269.10161.32. View

11.

Rhoden E, Morgentaler A . Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003; 170(6 Pt 1):2348-51. DOI: 10.1097/01.ju.0000091104.71869.8e. View

12.

Park K, Kim S, Kim K, Paick J . Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int. 1999; 83(3):327-33. DOI: 10.1046/j.1464-410x.1999.00913.x. View

13.

Morgentaler A . Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. Eur Urol. 2007; 52(3):623-5. DOI: 10.1016/j.eururo.2007.04.005. View

14.

Lugg J, Rajfer J, Gonzalez-Cadavid N . Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology. 1995; 136(4):1495-501. DOI: 10.1210/endo.136.4.7534702. View

15.

Lefkowitz G, Taneja S, Brown J, Melamed J, Lepor H . Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol. 2002; 168(4 Pt 1):1415-8. DOI: 10.1016/S0022-5347(05)64463-1. View

16.

Agarwal P, Oefelein M . Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005; 173(2):533-6. DOI: 10.1097/01.ju.0000143942.55896.64. View

17.

Marks L, Mazer N, Mostaghel E, Hess D, Dorey F, Epstein J . Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006; 296(19):2351-61. DOI: 10.1001/jama.296.19.2351. View

18.

Hoffman M, DeWolf W, Morgentaler A . Is low serum free testosterone a marker for high grade prostate cancer?. J Urol. 2000; 163(3):824-7. View

19.

Schultheiss D, Badalyan R, Pilatz A, Gabouev A, Schlote N, Wefer J . Androgen and estrogen receptors in the human corpus cavernosum penis: immunohistochemical and cell culture results. World J Urol. 2003; 21(5):320-4. DOI: 10.1007/s00345-003-0371-y. View

20.

Heracek J, Hampl R, Richard H, Hill M, Martin H, Starka L . Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids. 2007; 72(4):375-80. DOI: 10.1016/j.steroids.2007.01.004. View